ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
- Details
- Category: Liver Cancer/HCC
- Created on Tuesday, 01 October 2013 00:00
Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.
ICAAC 2013: Is HCV Infection Increasing Among HIV+ Gay Men in Japan?
- Details
- Category: HCV Sexual Transmission
- Created on Sunday, 22 September 2013 00:00
The incidence of acute hepatitis C virus (HCV) coinfection has increased in recent years at the largest HIV clinic in Japan, with almost all cases occurring among men who have sex with men, according to a poster presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. For those treated early with pegylated interferon plus ribavirin, the cure rate was high at 80%.
ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected
- Details
- Category: HIV/HCV Coinfection
- Created on Tuesday, 17 September 2013 00:00
Effective interferon-based therapy that produces sustained virological response (SVR) led to significant reductions in liver decompensation, HIV disease progression, and both overall and liver-related mortality among HIV/HCV coinfected patients, according to a presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.
ICAAC 2013: Treatment of HCV Genotypes 2/3 in HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Created on Tuesday, 24 September 2013 00:00
HIV/HCV coinfected patients, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV negative people to pegylated interferon plus ribavirin after taking into account other factors associated with poor treatment response, according to an Italian study presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. Advanced liver fibrosis was common in the coinfected group, supporting the need for early treatment.
ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding
- Details
- Category: Herpes
- Created on Tuesday, 17 September 2013 00:00
An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.
Web Design and Development by